MedTrace Logo

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

NCT05402020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17018

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

The real world study aims to assess effectiveness and safety profile between tiotropium/olodaterol (Tio/Olo) and inhaled corticosteroids(ICS) / Long-acting β2-agonists (LABA) in patients with chronic obstructive pulmonary disease (COPD) in Taiwan. The data used in this study will come from the Taiwan National Health Insurance (NHI) claims data between 2014 and 2019.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium (Tio)

Tiotropium (Tio)

DRUG

Inhaled corticosteroids (ICS)

Inhaled corticosteroids (ICS)

DRUG

Olodaterol (Olo)

Olodaterol (Olo)

DRUG

Long-acting β2-agonists (LABA)

Long-acting β2-agonists (LABA)

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-02-13
Completion
2023-02-13

Countries

  • China

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05402020 on ClinicalTrials.gov